Strategic Collaboration Potential PolyActiva is actively partnering with RareSight, Inc. to develop targeted therapies for rare pediatric retinal diseases, creating direct sales opportunities through co-development, licensing, and access to pediatric ophthalmology networks.

Long-acting Implant Value The proprietary biodegradable ocular implants provide zero-order drug release over six to twelve months, enabling recurring revenue models, clinic adoption for chronic conditions, and upsell potential into glaucoma and retinal indications.

Funding and Scale Readiness Recent Series C funding underscores capacity to scale local manufacturing and clinical development, supporting partnerships with larger pharma players seeking platform-based long-acting eye therapies.

Leadership and Governance Signal Appointments of a Chief Scientific Officer and Chief Financial Officer indicate strengthened R&D execution and financial planning, enhancing appeal as a collaboration or licensing partner for ophthalmic portfolios.

Market Engagement Footprint Active industry engagement through Eyecelerator at AAO and a Melbourne base with local manufacturing positions PolyActiva to engage providers, pediatric clinics, and regional distributors for early access programs and trials.